MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$7,659K
Net Income
-$107,424K
Net Profit Margin
-1402.59%
EPS
-$0.8
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
7,659
15,048
23,017
13,782
Research and development
82,595
80,737
88,652
94,747
General and administrative
37,824
34,843
33,075
30,512
Total operating expenses
120,419
115,580
121,727
125,259
Operating loss
-112,760
-100,532
-98,710
-111,477
Interest income
5,797
5,205
6,476
6,714
Change in fair value of investments, net
329
-904
-3,552
3,439
Loss from equity method investment
-
-
0*
-
Change in fair value of contingent consideration
-
-
0*
-
Total other income, net
6,126
4,301
2,924
10,153
Net loss
-106,634
-96,231
-95,786
-101,324
Unrealized (loss) gain on marketable securities
-790
-1,272
42
337
Other comprehensive gain from equity method investment
-
-
0
-
Comprehensive loss
-107,424
-97,503
-95,744
-100,987
Basic EPS
-0.8
-0.81
-0.825
-0.92
Diluted EPS
-0.8
-0.81
-0.825
-0.92
Basic Average Shares
133,480,000
118,490,000
116,084,000
110,188,000
Diluted Average Shares
133,480,000
118,490,000
116,084,000
110,188,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$107,424K
(-5.67%↓ Y/Y)
Interest income
$5,797K
(-21.68%↓ Y/Y)
Change in fair value of
investments, net
$329K
(-75.43%↓ Y/Y)
Net loss
-$106,634K
(-5.31%↓ Y/Y)
Unrealized (loss) gain on
marketable securities
-$790K
(-95.54%↓ Y/Y)
Total other income,
net
$6,126K
(-29.92%↓ Y/Y)
Operating loss
-$112,760K
(-2.51%↓ Y/Y)
Collaboration revenue
$7,659K
(-46.23%↓ Y/Y)
Total operating
expenses
$120,419K
(-3.08%↓ Y/Y)
Research and development
$82,595K
(-14.88%↓ Y/Y)
General and
administrative
$37,824K
(39.03%↑ Y/Y)
Buy us a coffee
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)